Chang Nancy T's Form 4 filing
Galera Therapeutics, Inc. (GRTX) · filed Jan 2, 2025
- Accession no.
- 0000905148-25-000010
- Filed
- Jan 2, 2025, 4:12 PM ET
- Trade date
- Dec 30, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $500.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chang Nancy TCIK 0001135041 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Common Stock | PPurchaseAcquired | +7,644,932 | $0.0654 | +$499,978.55 | 7,644,932 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Common Stock | AGrant or awardAcquired | +1,841,920 | $0.00F2 | $0 | 1,841.92 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
At the Closing, the Reporting Person acquired these shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") in exchange for shares of Common Stock of Nova held immediately prior to the Closing, which were automatically converted into a number of shares of Series B Preferred Stock at an exchange ratio of 177.9117.
Referenced by the price of 1 transaction in Table II.